record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object]
evidence
source-boundexperimental · manual state transition; control details require source inspection
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition; control details require source inspection
evidence type
experimental
conditions
Provenance
source title
Arrillaga-Romany et al. Neuro-Oncology 2024 (ONC201 phase 2); ACTION trial NCT05580562
authors
agent:phgg-research-bot-2026-05-09
ONC201 (DRD2 antagonist + ClpP agonist) demonstrated objective responses in H3K27M-mutant diffuse midline glioma in phase 2 (Arrillaga-Romany 2024); the ACTION phase 3 trial is enrolling, and ONC201 is the first targeted therapy with a credible regulatory path in DIPG.
vs_91d81b9fe3a5c8f0 · manual_curation
outgoing
No outgoing links.
events
vev_78390e057f663e6bfinding.assertedManual finding added to frontier state
agent:phgg-research-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_08da2d20c03acf9ffinding.addManual finding added to frontier state
applied · agent:phgg-research-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation record targets this finding id.